Dextrose Monohydrate

證據等級: L5

預測適應症: 0 個

Dextrose Monohydrate: Drug Repurposing Evaluation Report

One-Sentence Summary

Dextrose Monohydrate is a simple monosaccharide (glucose) widely used as a pharmaceutical excipient, caloric supplement, and fluid replacement therapy. The TxGNN model did not generate any predicted new indications for this compound, and critical data gaps remain in mechanism of action and safety documentation.

Quick Overview

Item	Content
Original Indication	Not available (license detail fields empty)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	N/A
Malaysia Market Status	✓ Marketed (已上市)
Number of Registrations	31
Recommended Decision	Hold

Why Are There No Predictions?

Dextrose Monohydrate (glucose monohydrate) is the hydrated form of D-glucose, primarily used in clinical settings as:

An intravenous caloric supplement and fluid replacement
A vehicle/excipient in pharmaceutical formulations
A treatment for hypoglycaemia

Unlike conventional therapeutic molecules that interact with specific biological targets, dextrose is an endogenous metabolite — a fundamental energy substrate in human physiology. It does not have a narrowly defined pharmacological mechanism of action in the way that receptor agonists, enzyme inhibitors, or ion channel modulators do. This characteristic makes it poorly suited for knowledge-graph-based drug repurposing approaches like TxGNN.

The TxGNN model relies on mapping drugs to DrugBank identifiers and then traversing drug–disease relationships in a biomedical knowledge graph. In this case, the DrugBank ID was not resolved (null), which means the drug could not be anchored in the knowledge graph. Without a valid node in the graph, no disease predictions can be generated. Additionally, dextrose’s role as a basic metabolite rather than a targeted therapeutic agent means it lacks the specific molecular interaction profile that TxGNN leverages for repurposing predictions.

Clinical Trial Evidence

Not applicable — no predicted indications were generated by TxGNN.

Literature Evidence

Not applicable — no predicted indications were generated by TxGNN.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(Not available)	(Not available)	(Not available)	(Not available)

Note: 31 registrations were retrieved from the NPRA database, but detailed license information (authorization numbers, product names, dosage forms, and approved indication text) was not populated in the evidence pack. The raw data needs to be re-extracted with complete field mapping.

Safety Considerations

Please refer to the package insert for safety information.

Key safety data (warnings, contraindications, and drug interactions) could not be retrieved. This has been identified as a Blocking data gap (DG001) that must be resolved before any further evaluation can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: Dextrose Monohydrate is a basic metabolic substrate (glucose) with no specific pharmacological target, making it an unsuitable candidate for TxGNN-based drug repurposing. The model returned zero predicted indications, and critical data fields — including DrugBank ID, mechanism of action, license details, and safety information — are all missing.

To proceed, the following is needed:

Resolve DrugBank mapping — Confirm whether DrugBank entry DB09341 (Glucose) or another entry applies, and re-run the prediction pipeline with a valid DrugBank ID
Populate license details — Re-query NPRA with complete field extraction to fill in the 31 empty registration records
Obtain safety documentation (DG001, Blocking) — Download and parse package insert PDFs from the regulatory authority for warnings and contraindications
Re-evaluate candidacy — Even with a resolved DrugBank ID, dextrose as an endogenous metabolite may remain fundamentally unsuitable for knowledge-graph-based repurposing; consider excluding basic metabolites/excipients from future screening runs
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.